Haemophilia in the developing world: the Brazilian experience

Haemophilia. 2002 May;8(3):199-204. doi: 10.1046/j.1365-2516.2002.00638.x.

Abstract

The success of haemophilia treatment is based on well-established criteria, and the use of clotting factor concentrates is fundamental. These strategies are seen in the developed world when measures of quality of life are studied or when disabilities are evaluated among haemophilic patients. At the same time, countries in the developing world, with almost 80% of the haemophilia population, are making tremendous efforts to change their diagnosis and treatment methods, in order to improve their healthcare and therefore be able to promote better life for haemophiliacs. However, these goals are threatened when there are many social needs and few economic resources. There is wide variation in conditions in these countries, depending on what has already been done, how many patients the country has, how the blood banking services are planned and obviously, what are the interested parties. Even with so many difficulties, there are ways to work towards and reach the most important goal, which is to prepare the haemophiliacs to be citizens that are as productive and capable of working as are the nonhaemophiliacs. Each country has to take its part; the commitment of the community, physicians and government will be needed to design a model that is compatible with all the necessities and possibilities, and is understood by all the persons involved.

Publication types

  • Review

MeSH terms

  • Blood Banks / organization & administration
  • Blood Coagulation Factors / therapeutic use
  • Brazil
  • Comprehensive Health Care
  • Developing Countries*
  • Hemophilia A / economics
  • Hemophilia A / epidemiology
  • Hemophilia A / therapy*
  • Humans

Substances

  • Blood Coagulation Factors